Entera Bio ( (ENTX) ) has released its Q3 earnings. Here is a breakdown of the information Entera Bio presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Entera Bio Ltd. is a clinical-stage biotechnology company based in Jerusalem, Israel, focusing on developing oral tablet formats of peptides or protein replacement therapies, primarily targeting chronic medical conditions with its proprietary N-Tab™ platform.
In its latest earnings report for the quarter ended September 30, 2025, Entera Bio highlighted its ongoing development efforts, particularly the advancement of its EB613 program, which is being developed as the first oral treatment for osteoporosis. The company also announced a collaboration with OPKO Health, Inc. for the development of an oral dual agonist GLP-1/glucagon peptide for obesity and metabolic disorders.
Financially, Entera Bio reported a net loss of $8.4 million for the nine months ended September 30, 2025, compared to a net loss of $7.2 million in the same period in 2024. The company’s operating expenses increased due to higher research and development costs, primarily driven by the advancement of its clinical programs. Despite the losses, Entera Bio managed to raise $13.5 million through financing activities, which included a collaboration agreement with OPKO Health, Inc.
Looking forward, Entera Bio’s management remains focused on advancing its clinical programs, particularly the EB613 Phase 3 study for osteoporosis. The company is also exploring additional financing options and strategic collaborations to support its research and development activities. Entera Bio’s management believes that its current funds will sustain operations through the third quarter of 2026, although additional capital will be required for future phases of its clinical programs.